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Dendritic cells express the skeletalmuscle ryanodine receptor
(RyR1), yet little is known concerning its physiological role and
activation mechanism. Here we show that dendritic cells also
express the Cav1.2 subunit of the L-type Ca2 channel and that
release of intracellular Ca2 via RyR1 depends on the presence
of extracellular Ca2 and is sensitive to ryanodine and nifedip-
ine. Interestingly, RyR1activation causes a very rapid increase in
expression of major histocompatibility complex II molecules
on the surface of dendritic cells, an effect that is also observed
upon incubation of mouse BM12 dendritic cells with trans-
genic T cells whose T cell receptor is specific for the I-Abm12
protein. Based on the present results, we suggest that activa-
tion of the RyR1 signaling cascade may be important in the
early stages of infection, providing the immune system with a
rapid mechanism to initiate an early response, facilitating the
presentation of antigens to T cells by dendritic cells before
their full maturation.
Ca2 signals regulate a variety of functions in eukaryotic cells
frommuscle contraction andneuronal excitability to gene tran-
scription, cell proliferation, and cell death. To efficiently utilize
Ca2 as a second messenger, cells are equipped with an essen-
tial toolbox kit composed of a variety of proteins that allow
Ca2 ions to flow into the cytoplasm and be removed from the
cytoplasm, proteins that store/buffer Ca2 in intracellular
organelles, and proteins acting as sensors for intracellular Ca2
levels as well as Ca2-regulated enzymes (1, 2). In both excita-
ble and non-excitable cells, generation of an intracellular Ca2
transient is due to the release of Ca2 from intracellular stores
via inositol 1,4,5-trisphosphate or ryanodine receptors (RyRs)2
present on the endoplasmic (ER)/sarcoplasmic reticulum
membranes and opening of Ca2 channels present on the
plasmamembrane. Both the amplitude and the frequency of the
Ca2 signal can be sensed by specific proteins allowing a cell to
respond appropriately to signals, which apparently only give
rise to an increase in the intracellular Ca2 concentration
([Ca2]i). In general, non-excitable cells are endowed with ino-
sitol 1,4,5-trisphosphate receptors which open in response to
the generation of the receptor coupled second messenger ino-
sitol 1,4,5-trisphosphate, allowing Ca2 to flow out of the ER.
On the other hand, excitable cells, which need to respond to
signals within milliseconds, are equipped with RyR Ca2 chan-
nels (1). Regulation of the latter class of proteins is notmediated
by the generation of a second messenger but rather through
coupling with another protein component present on the
plasma membrane, the L-type Ca2 channel (3). In fact, in car-
diac and skeletal muscles, signaling to the RyR is coupled to the
dihydropyridine receptor (DHPR) L-typeCa2 channels, which
sense changes in membrane potential thereby activating Ca2
release from the sarcoplasmic reticulum. L-type Ca2 channels
are composed of an 1 subunit (Cav), which spans the mem-
brane and contains the pore region, and the four additional
subunits1,2, , and . There are at least four genes encoding
the 1 subunits (Cav1.1-Cav1.4), and all mediate L-type Ca2
currents, although their products are preferentially expressed
in different tissues/subcellular locations (3, 4). Cav1.1 is local-
ized in the transverse tubules and is involved in skeletal muscle
excitation-contraction coupling; Cav1.2 is expressed in cardiac
and smoothmuscle cells, endocrine cells, and pancreatic cells
as well as in neuronal cell bodies and is involved in cardiac
excitation-contraction coupling, hormone release, transcrip-
tion regulation, and synaptic integration. Cav1.3 and Cav1.4
have a more widespread distribution, including neuronal cell
bodies, dendrites, pancreatic cells, cochlear hair cells, adrenal
gland, and mast cells where they are involved in hormone/neu-
rotransmitter release, regulation of transcription, and synaptic
regulation (4).
Ryanodine receptors belong to a family of intracellular Ca2
release channels composed of at least three different isoforms
that have been characterized extensively biochemically, func-
tionally, and at the molecular level (5–7). Type 1 RyRs are
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encoded by a gene on human chromosome 19 and are mainly
expressed in skeletal muscle and to a lower extent in Purkinje
cells. Mutations in this gene are associated with the rare neuro-
muscular disorders malignant hyperthermia, central core dis-
ease, and some forms of multiminicore disease (8, 9). Type 2
RyR is mainly expressed in cardiac muscles and cerebellum.
Mutations in its gene are associated with genetic variants of
congestive heart failure, namely catecholaminergic polymor-
phic ventricular tachycardia and arrhythmogenic right ventric-
ular dysplasia (10, 11). Type 3 RyRs are expressed in a variety of
excitable tissues aswell as in immaturemuscle cells (12). Recent
reports have demonstrated that type 1 RyRs are also expressed
in some cells of the immune system (13), particularly B-lym-
phocytes anddendritic cells (DCs)where their pharmacological
activation gives rise to a rapid and transient increase in the
intracellular Ca2 concentration (14–19).
Although both B-lymphocytes and DCs can act as antigen
presenting cells and initiate T cell-driven immune responses
(20), DCs play a central role in the immune system; they are
strategically located in peripheral tissues where they continu-
ously sample their environment for the presence of antigens.
Upon encounter with microbial products or tissue debris,
immature DCs (iDCs) stop endocytosing, undergo maturation,
and become the most potent antigen presenting cells known.
Mature DCs up-regulate co-stimulatory molecules and anti-
gen-presenting molecules, transcribe mRNA for specific cyto-
kines, and migrate to secondary lymphoid organs where they
interact with naïve T cells to initiate specific immune responses
(21). Complete maturation of DCs is thought to require at least
10–20 h (22, 23). The involvement of Ca2 signaling events in
DC maturation had been postulated for a number of years, but
only recently was it demonstrated that RyR1-mediated Ca2
signals can act synergistically with signals generated via Toll-
like receptors driving DC maturation (17, 19). Experimentally,
iDCs can be induced to undergo maturation by treatment with
high (M) concentrations of lipopolysaccharide. Physiologi-
cally, however, an inflamed region most likely contains a mix-
ture of bacterial components, tissue and cellular debris, and
other cellular components, including ions released from dying
cells.
Several questions emerge concerning the role(s) of RyRs in
DCs. (i) Why do these cells utilize the rapid acting RyRs to
achieve such a slow process such as maturation; are RyRs
involved in other aspects of DC function? (ii) What is the phys-
iological route of RyR1 activation inDCs? In skeletalmuscle the
Cav1.1 subunit of the DHPR L-type Ca2 channel present on
the transverse tubular membrane acts as a voltage sensor and
interacts directly with the RyR1 to initiate Ca2 release. Are
DCs equipped with a similar signaling pathway?
In the present report we show that DCs are endowed with a
DHPRwhich is activated bymembrane depolarization and trig-
gers Ca2 release via RyR1. More importantly we show that
activation of this signaling pathway is both necessary and suffi-
cient to cause the rapid release of an intracellular pool of MHC
class II molecules onto the plasma membrane. We hypothesize
that a such a rapid signalingmachinerymay be important under
specific conditions, namely in the very early phases of an
immune response when T cells and iDCs may become inti-
mately connected; engagement of T cell receptors with the
MHC class II molecules on the surface of iDCs rapidly activates
T cells to release factors stimulating an increase in the level of
expression of MHC class II molecules on the surface of iDCs,
possibly supporting very early activation steps of T cells.
EXPERIMENTAL PROCEDURES
Isolation and Generation of Dendritic Cells—Human iDCs
were generated from peripheral bloodmononuclear leukocytes
as previously described (17). Brieflymonocyteswere purified by
positive sorting using anti-CD14 conjugated magnetic
microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).
Sorted monocytes were cultured for the following 5 days in
differentiation medium containing RPMI, 10% fetal calf serum,
glutamine, nonessential amino acids, and antibiotics (Invitro-
gen) supplemented with 50 ng/ml granulocyte-macrophage
colony-stimulating factor (Laboratory Pablo Cassara`, Buenos
Aires, Argentina) and 1000units/ml interleukin 4 (a gift fromA.
Lanzavecchia, Bellinzona, Switzerland).
Murine dendritic cells were isolated by positive sorting from
spleens treatedwith collagenaseD (1mg/ml;Worthington Bio-
tech; Lakewood, NJ) using anti-CD11c-coated magnetic
MicroBeads according to the manufacturer’s instructions
(Miltenyi Biotech). The phenotype of cells was evaluated before
experiments by flow cytometry using a FACSCalibur instru-
ment equipped with Cell Quest software (BD Biosciences) as
previously described (17).
Preparation of Necrotic Cell Extracts—Extracts were pre-
pared essentially as described (17); briefly, cultured HEK293
cells (1–1.5  107) were harvested, rinsed twice with PBS,
resuspended in PBS, and subjected to 5 cycles of freeze-thaw-
ing. Viability was assessed by trypan blue exclusion and was
5%. Large cellular debris were removed by centrifugation, and
their supernatant was filtered twice through a 0.22-m Milli-
pore filter and stored at70 °C.Where indicated, extracts were
dialyzed overnight at room temperature against PBS using a
3000 Da cut-off Spectrapore dialysis membrane (Spectrum
Laboratories). Extracts were then centrifuged and filtered twice
through 0.22-mMillipore filters.
Stimulation of iDC and CD83 Expression—In vitro derived
iDCs were cultured for 4 h at 37 °C in the presence of 1 g/ml
LPS (from Salmonella abortus equi, Sigma) or in the presence
of 1 ng/ml LPS supplemented with supernatants from necrotic
cells. Briefly, necrotic cell extracts obtained from 1 107 cells
(1.2 ml) were added to 0.8  106 iDCs cultured in 1 ml of dif-
ferentiationmediumplus 1 ng/ml LPS; when nifedipine or dan-
trolene were used iDCs were pretreated at 37 °C for 45 min in
the dark with 10 M nifedipine (Calbiochem) or 20 M dan-
trolene (Sigma) before the addition of the necrotic extract. Cells
were harvested, and surface expression of CD83 was investi-
gated by flow cytometry using FITC-labeled anti-CD83 mono-
clonal antibodies (BD Pharmingen) on paraformaldehyde (1%
in PBS) fixed cells.
Single-cell Intracellular Ca2 Measurements—Measure-
ments were performed on fura-2 (Molecular Probes, Eugene,
OR)-loaded iDCs. In some experiments fura-2 loading and
incubation with 500 M ryanodine (Calbiochem) were per-
formed simultaneously. After loading, cells were rinsed once,
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resuspended in Krebs-Ringermedium and allowed to adhere to
glass coverslips, which were then mounted onto a 37 °C ther-
mostatted chamber thatwas continuously perfusedwithKrebs-
Ringer medium containing 1 mM CaCl2. Individual cells were
stimulated with the indicated agonist by way of a 12-way
100-mm diameter quartz micromanifold computer-controlled
microperfuser (ALA Scientific, Westbury, NY) as previously
described (15). Online (340 nm, 380 nm, and ratio) measure-
ments were recorded using a fluorescent Axiovert S100 TV
invertedmicroscope (Carl Zeiss, Jena, Germany) equippedwith
a 40 oil immersion Plan Neofluar objective (0.17 NA) and
filters (BP 340/380, FT 425, BP 500/530) and attached to a
Hamamatsu multiformat CCD camera. Cells were analyzed
using an Openlab imaging system, and the average pixel value
for each cell wasmeasured at excitationwavelengths of 340 and
380 nm, as previously described (15).
Membrane PotentialMeasurements—Changes inmembrane
potential were assessed after the changes in fluorescence of the
lipophilic dye bis-(1,3-diethylthiobarbiturate)-trimethineox-
onal (bis-oxonol) as described by the manufacturer (Molecular
Probes). iDCs (0.65 106 cells/ml) were rinsed, resuspended in
PBS, and added to a cuvette containing 200 nM bis-oxonol in
PBS. After allowing the dye to equilibrate, changes in fluores-
cence were monitored with a PerkinElmer Life Sciences LS50
spectrofluorometer equipped with magnetic stirrer and ther-
mostatted at 37 °C.
Immunofluorescence Analysis—Immunofluorescence analy-
sis was performed as indicated onmethanol-fixed or methanol:
acetone (1:1)-fixed iDCs using rabbit anti-Cav1.2 antibody
(anti-CCAT, a gift from Natalia Gomez-Ospina and Prof.
Ricardo Dolmetsch, Department of Neurobiology, Stanford
University School of Medicine, Stanford CA), goat anti-RyR
(Santa Cruz Biotechnology Inc.), mouse anti-human HLA DR
(Caltag Laboratories, BurlingameCA) followed by Alexa Fluor-
488-conjugated chicken anti-rabbit IgG, Alexa Fluor-555-con-
jugated donkey anti-goat IgG (Molecular Probes), or PE-conju-
gated goat anti-mouse IgG (Southern Biotech). Fluorescence
was visualized using a 100 Plan NEOFLUAR oil immersion
objective (NA 1.3) mounted on a Zeiss Axiovert 100 as previ-
ously described (17).
Immunoblotting and Reverse Transcription PCR Analysis—
For Western blots iDCs (1  107 cells) were washed 3 times
with PBS, and the pellet was then resuspended in 500 l of
detergent extraction buffer containing 1% Nonidet, 0.5%
sodium deoxycholate, 150 mMNaCl, 5 mM EDTA, 50 mM Tris-
HCl, pH 8.0, plus anti-proteases (EDTA-free, Roche Applied
Science), passed through a 25-gauge needle, and incubated for 5
min at 95 °C. The solubilized proteins from 1  106 cells were
loaded in each lane and separated on a 6% SDS-PAG. Proteins
were transferred onto nitrocellulose, and the blots were probed
with a rabbit anti-Cav1.2 antibody (1:2000) followed by perox-
idase-conjugated protein G (1:50000. Fluka Biochemicals,
Buchs, Switzerland). The immunopositive bands were visual-
ized by autoradiography using the Super signal West Dura
chemiluminescence kit from Thermo Scientific.
Reverse transcription PCR was performed as previously
described (15). Total RNAwas isolated from8 106 iDCs using
the ULTRASPEC RNA isolation system (Biotex Labs) and
reverse-transcribed using a cDNA synthesis kit following the
instructions provided by themanufacturer (Roche Applied Sci-
ence). Approximately 100 ng of cDNA were used per PCR
amplification using anApplied Biosystems 2720 thermal cycler.
The following primers spanning exons 15–16 were used to
amplify the Cav1.2 transcript: forward, 5-AAA TTT CCCT
GGG ACTG TTG; reverse, 5-GGT TAT GCCC TCCC CTG.
Such primers yield a DNA fragment of300 bp when amplify-
ing cDNA; amplification from genomic DNA would be highly
unlikely under normal PCR conditions as the expected frag-
ment is too large (2800 bp). Amplification conditions were 5
min at 95 °C followed by 35 cycles of 30 s annealing at 92 °C, 40 s
extension at 50 °C, and 40 s denaturation at 72 °C followed by a
final extension for 5 min at 72 °C using the 2.5 Master Mix
Taq polymerase from Eppendorf. The products of the PCR
reaction were separated on a 6% polyacrylamide gel, and the
bands were visualized by ethidium bromide staining.
Functional Properties of iDCs—Endocytosis was studied by
incubating iDCs in RPMI medium containing FITC-labeled
dextran (final concentration 0.5 mg/ml; Fluka Chemicals,
Buchs, Switzerland) for 30min at 37 °C. Cells were washed in
ice-cold PBS 2 times and fixed with 1% paraformaldehyde,
and the number of FITC-positive cells was assessed by flow
cytometry.
Surface expression ofMHC class I and class II molecules was
monitored in iDCs stimulated with 10 mM caffeine for 1–60
min at 37 °C or on iDCs stimulated with 100 mM KCl, necrotic
cell extracts, 100 M ATP, or 1 g/ml LPS for 1 min. To mon-
itor surface expression of MHC class I and II molecules, stim-
ulated cells were washed with ice-cold PBS, labeled, and ana-
lyzed by flow cytometry using FITC-labeled anti-human HLA
DRandHLAA,B,Cor, in the case ofmouseCD11c cells, with
FITC-labeled anti mouse I-Ab monoclonal antibody (BD
Pharmingen).
In Vivo Investigation of Mouse DC-T cell Interactions;
Increase in [Ca2]i and RapidMHCClass II Induction—CD11c
positive DCs were isolated from the spleens of either B6.C-H-
2bm12Ly 5.1 mice (abbreviated BM12DC) or B6.Ly 5.1 mice (a
generous gift of Prof. Ed Palmer, Department of Biomedicine,
Basel University Hospital, Basel, Switzerland). T-lymphocytes
were isolated from the lymphnodes ofABMRg/mice. These
T cells recognize the I-Abm12 protein expressed on the surface
of B6.C-H-2bm12.Ly5.1DCs but do not recognize the I-Ab pro-
tein expressed on the surface of B6.Ly5.1 DCs (24). T-lympho-
cytes were divided in two groups; one group was left untreated,
whereas the other was incubated with 100 nM charybdotoxin
(Alexa Biochemicals) for 45 min to block K channels (25),
after which the cells were washed to remove excess toxin.
ForCa2 imaging BM12DCwere loadedwith the fluorescent
Ca2 indicator fluo-4 AM (Invitrogen; 5 M final concentra-
tion) for 60 min at 37 °C. In some experiments BM12DCs were
simultaneously incubated with 500 M ryanodine (Calbio-
chem) and fluo-4AM.Cells were thenwashed and resuspended
in Krebs-Ringer containing 1mMCaCl2 and 0.2% bovine serum
albumin. BM12DC were allowed to adhere to glass coverslips
which were then mounted on a 37 °C thermostatted chamber.
Experiments were started by adding T-lymphocytes to the cov-
erslip onto which the BM12DCs had been applied. Changes in
RyR1 Signaling in Dendritic Cells
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fluo-4 fluorescence were monitored with a Nikon Eclipse
TE2000-E fluorescent microscope equipped with a CFI APO
TIRF 60 objective. Changes in fluorescence were detected by
exciting at 488 nm and recording the emission at 510-nm via an
electron multiplier C9100–13 Hamamatsu CCD camera.
Image analysis was performedwith theMetaMorph (Molecular
Devices) analysis software package.
For MHC II induction untreated T-lymphocytes or T-lym-
phocytes preincubated with 100 nM charybdotoxin (Alexa Bio-
chemicals) for 45 min and washed to remove excess toxin were
used. Both batches of T cells were placed in 1.5-ml Eppendorf
tubes together with the CD11c positive B6 or B6.C-H-2bm12
DCs. Cells were spun down for 30 s using a Tomy PMC-060
capsulefuge and incubated at 37 °C for an additional 5 min.
They were then diluted with ice-cold PBS, washed, and labeled
with FITC-anti-mouse I-Ab, biotin-labeled anti-CD11c plus
APC (allophycocyanin)-labeled streptavidin, and PE-labeled
anti-CD45.1 (all from BD Pharmingen). Expression of MHC
class II molecules was determined on triple positive cells by
flow cytometry.
Statistical Analysis and Software Programs—Statistical anal-
ysis was performed using the Student’s t test for unpaired sam-
ples; means were considered statistically significant when the p
value was 0.05. The Origin computer program (Microcal
Software, Inc., Northampton,MA) was used to generate graphs
and for statistical analysis. Figures were assembled using Pho-
toshop Adobe.
RESULTS
Upstream Events Leading to RyR1 Activation—In an earlier
report (17) we showed that (i) iDCs only express the type 1 RyR
isoform, (ii) the addition of caffeine, 4-chloro-m-cresol, or KCl
to iDC causes a RyR1-dependent increase in the intracellular
Ca2 concentration ([Ca2]i), and (iii) the signaling cascade
activated by the Ca2 increase acts synergistically with signals
generated via Toll-like receptors, stimulating DC maturation
(17). Because RyRs are present in intracellular membranes and
are not directly accessible to stimulation, our first aim was to
identify events upstream from RyR1 activation by first search-
ing for, and then using amore physiological stimulus leading to
DC maturation.
Fig. 1 shows that treatment of iDCs with a suboptimal con-
centration of lipopolysaccharide (LPS 1 ng/ml) for 4 h in the
presence of necrotic cell extracts, a stimulus that has been
shown to cause maturation (26), leads to a significant increase
in the surface expression of CD83, a reliable phenotypicmarker
for DC maturation (17, 27, 28). The signals generated by the
addition of the necrotic cell extracts and leading to maturation
were significantly decreased by pretreatment of cells with dan-
trolene (p 0.034), an inhibitor of the RyR1 (29) and nifedipine
(p  0.019), a well known L-type Ca2 channel inhibitor (4).
The functional involvement of a nifedipine- and ryanodine-
sensitive Ca2 signal was confirmed by direct measurements of
the intracellular [Ca2] (Fig. 2, A and B). Individual fura-2
loaded iDCs were stimulated with filtered extracts from
necrotic cells. This treatment caused a transient and rapid
increase in [Ca2]i, which was significantly decreased (p 
0.0001) by preincubation of iDCs with 500 M ryanodine (Fig.
2A, inset) (at high concentrations ryanodine blocks the RyR (30,
31); dantrolene, which is used to inhibit RyR-signaling events, is
fluorescent and interferes with imaging when using fluorescent
Ca2indicators) or 10 M nifedipine (p  0.0001; Fig. 2A); in
fact, the mean  fluorescence induced by necrotic extracts was
0.210 0.011 in untreated cells and 0.134 0.094 and 0.029
0.008 in cells pretreated with 500 M ryanodine or 10 M nife-
dipine, respectively. A similar result was observed after the
addition of 100 mM KCl to iDCs (Fig. 2B). In the latter case, if
the experiments were performed in the absence of extracellular
Ca2 and in the presence of 100 M La3 to block Ca2 influx
(32) or on iDCs which had been pretreated with 500 M ryan-
odine or 10 M nifedipine, the mean increases in fluorescence
induced by the addition of 100 mM KCl were significantly
reduced (Fig. 2B; p  0.0001), indicating that the intracellular
Ca2 transient is dependent on the activation of the RyR1, on
influx of Ca2 from the extracellular medium, and is sensitive
to micromolar concentrations of nifedipine.
These results suggest that KCl and necrotic cell extracts may
act in a similar fashion; KCl causes membrane depolarization,
and this can be followed experimentally with the fluorescent
membrane potential dye bis-oxonol whereby depolarization
increases the fluorescence of bis-oxonol (Fig. 2C, left and cen-
tral panels), whereas hyperpolarization causes a decrease in
fluorescence. The addition of filtered necrotic cell extracts to
iDCs causes plasma membrane depolarization (Fig. 2C, right
panel), and the extent of depolarization is proportional to the
number of cells from which the extracts were prepared (not
shown); overnight dialysis of the necrotic extract against PBS
with a 3000-Da cut-off membrane abolished its depolarizing
effect (Fig. 2C, right panel).
FIGURE 1. Surface expression of CD83 induced by necrotic cell extracts is
sensitive to dantrolene and nifedipine. iDCs were treated for 4 h as indi-
cated, and the number of positive CD83 cells was determined by flow cytom-
etry on paraformaldehyde (1% in PBS) fixed cells. Stimulation with 1 ng/ml
LPS alone induced a small increaseCD83 surface expression; the concomitant
presence of supernatants from necrotic HEK293 cells, prepared as described
under “Experimental Procedures” increased CD83 significantly as compared
with iDCs treated with 1 ng/ml LPS (*, p  0.02). This effect was blocked by
pretreatment of iDCswith the RyR1 inhibitor dantrolene (20M; p 0.034) or
with the L-type Ca2 channel inhibitor nifedipine (10 M; p 0.019). Results
are expressed as themean (S.E.) % induction of CD83 surface expression of
at least three experiments carried out on iDCs purified frombloodof different
donors; values obtained by treating iDCs with 1 g/ml LPS were considered
100%.
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In cardiac and skeletal muscles, signaling to the RyR1 is cou-
pled to DHPR L-type Ca2 channels, which sense changes in
membrane potential thereby activating Ca2 release from the
sarcoplasmic reticulum. Because human iDCs express the 1
subunit of the DHPR (33), we wondered whether the depolar-
ization-coupled Ca2 release observed in iDC could be due to
the expression of a Cav1 isoform by these cells. Immunofluo-
rescence analysis using confocalmicroscopy onmethanol-fixed
iDCs labeled with anti-Cav1.2 Abs followed by Alexa Fluor-
488-conjugated anti-rabbit IgG (Fig. 3A, panel 1) and anti-MH-
CII Abs (Fig. 3A, panel 2) followed by PE-conjugated anti-
mouse IgG confirmed partial co-localization of the two
proteins on the plasma membrane of iDCs (Fig. 3A, panel 5).
We next verified if there was co-localization between Cav1.2
and the RyR by performing immunofluorescence analysis on
permeabilized acetone-methanol-fixed iDCs. Under these con-
ditionsCav1.2 appeared to be discretely distributedwithin iDCs
(Fig. 3B, panel 1), whereas immunostaining for the RyR1
showed a more reticular pattern of distribution (Fig. 3B, panel
2); merging the two images shows that part of the positive flu-
orescent signals obtained with anti-Cav1.2 and anti-RyR over-
lap (Fig. 3B, panel 5), indicating that the two proteins co-local-
ize within certain domains of iDCs. To confirm that the
antibodies recognize a protein corresponding to Cav1.2, we
performed Western blot analysis. Fig. 3C shows that the anti-
Cav1.2 Abs we used, which were specifically raised against the
COOH terminus of Cav1.2 (34), recognize a band in total iDC
extractsmigrating with an apparentmolecularmass of 200 kDa
as well as another immunopositive band with a slightly slower
mobility; very similar results were obtained by Gomez-Ospina
who used these Ab to identify Cav1.2 in neurons (34). Finally,
reverse transcription-PCR using primers specifically designed
FIGURE 2.Necrotic cell extracts andKCl induce anifedipine-sensitive increase in [Ca2] in iDCs aswell asmembranedepolarization.A and B, single cell
intracellular calcium measurements in fura-2-loaded iDCs. The traces in the insets show changes in the fura-2 fluorescence ratio (340/380 nm) in single iDC
perfused with necrotic cell extracts (A) or 100 mM KCl (B) Continuous line, no pretreatment; dashed line, cells pretreated with 500 M ryanodine for 60 min.
Experiments were performed in Krebs-Ringer containing 1 mM Ca2 except when La3(100 M) was added, in which case only contaminating Ca2 was
present. When nifedipine or ryanodine were used, cells were preincubated with 10 M nifedipine or 500 M ryanodine during the fura-2 loading. The
histograms represent the mean (S.E. of the indicated n values)  increase in fluorescence, calculated by subtracting the peak fluorescence ratioresting
fluorescence ratio): *, p 0.0001. C, membrane potential changes were monitored by following the change in fluorescence of bis-oxonol as detailed under
“Experimental Procedures.” After allowing thedye to equilibrate, either KCl or filterednecrotic extracts obtained from2.9106 cellswere added to the cuvette
while continuouslymonitoring the emission at 516 nm. An upward deflection indicatesmembrane depolarization. Experimentswere carried out at least three
timesgiving similar results. Themean (S.E.) of 4–6 valueswereused togenerate the fluorescence-KCl dose-dependent curve shown inpanel C (center).a.u.,
arbitrary units.
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to amplify the human Cav1.2 transcript generated a band cor-
responding to the expected size (Fig. 3D) when amplifying
cDNA. PCR amplification using primers specific for human
Cav1.1 and Cav1.3 failed to amplify any band from cDNA of
DCs (results not shown).
Rapid Events Occurring after RyR1Activation—Wewere also
interested in investigating if activation of the RyR1 leads to any
direct changes in DCs. Immature DCs are extremely efficient at
endocytosing (20, 21), so our first experiments were aimed at
determining whether pretreatment of cells with a RyR1 agonist
affects their capacity to endocytose FITC-labeled dextran. No
difference in mean fluorescent intensity was observed between
untreated iDCs or cells treated with 10 mM caffeine or 100 mM
KCl. In 5 different experiments the mean  S.E. % of FITC-
positive cells was 98.5 18.7% for cells pretreated with 100mM
KCl and 100% for iDCs (p	 0.899).
We next investigated whether RyR1 activation is linked to
surface expression ofMHCmolecules. DCs express one pool of
MHC class I molecules that are syn-
thesized and loaded with antigenic
peptides in the ER and two main
populations of MHC class II mole-
cules; one pool is synthesized de
novo and is loaded with processed
antigenic peptides in the ER,
whereas the other is preformed and
located within re-cycling endo-
somes (20). Immature dendritic
cells were stimulated for 1–60 min
with the RyR1 agonist caffeine,
stained with anti-MHC I or anti-
MHC II antibodies, and processed
by flow cytometry. Fig. 4A shows
that as early as 1 min after stimula-
tion, there was a significant increase
in surface fluorescence associated
withMHC class II expression which
then decayed back to resting levels
after 60 min of incubation at
37 °C. The increase inmean fluores-
cence intensity was reproducible
and was specifically generated via
DHPR-RyR1 signaling because (i) it
also occurred after the addition of
necrotic cell extracts and 100 mM
KCl and (ii) the latter effects could
be blocked by pretreatment of iDCs
with dantrolene and nifedipine (Fig.
4B), (iii) it did not occur in cells
treated with high levels (1 g/ml) of
LPS or with ATP, the latter agonist
also generating a Ca2 signal, but
via inositol 1,4,5-trisphosphate
receptor activation (35), and (iv)
KCl and necrotic extracts did not
affect surface expression of MHC
class I molecules (Fig. 4C). Such an
effect may represent a specific and
physiological pathway utilized by iDCs to rapidly expressMHC
class II molecules on their surface. The above-mentioned
experimentswere performedon “in vitro” generatedDCs;when
the same experiments were carried out on naturally occurring
DCs isolated from mouse spleens, the addition of 100 mM KCl
and necrotic cell extracts also caused a significant increase in
surface expression of MHC class II molecules (Fig. 5A).
These findings are intriguing because of their rapid time
course and because of their specificity but yield no informa-
tion regarding their physiological role. We wondered
whether the activation of the RyR1 signaling system could be
important under specific conditions, namely when iDCs are
present in an inflamed environment containing antigens as
well as T cells. Notably, the classical pathways for T cell
activation is via the inositol trisphosphate signaling pathway
which leads to an increase in the [Ca2]i by releasing Ca2
from intracellular stores and by opening Ca2 channels on
the plasma membrane (36). To compensate for the change in
FIGURE 3. Cav1. 2 is expressed in iDCs and shows partial co-localization with the RyR. A, immunofluores-
cence analysis on methanol fixed human iDCs. Shown are iDCs stained with rabbit anti-Cav1.2 polyclonal
antibodies followed by Alexa Fluor-488-conjugated anti-rabbit IgGs (1) or Alexa Fluor-488 conjugated anti-
rabbit IgGs alone (3) andmouse anti-MHC II (HLA DR) Abs followed by PE-conjugated goat anti-mouse Abs (2)
or PE conjugate goat anti-mouse Abs alone (4). Panel 5 shows the merged images, and yellow-orange pixels
indicate overlapping fluorescent signal; bars indicate 10 m. B, immunofluorescence analysis on acetone:
methanol fixed-iDCs (1). iDCs stained with rabbit anti-Cav1.2 polyclonal antibodies followed by Alexa Fluor-
488-conjugated anti-rabbit Abs or Alexa Fluor-488-conjugated anti-rabbit Abs alone (3) or goat anti-RyR poly-
clonal Ab followedbyAlexa Fluor-555 conjugated anti-goat Abs (2) or Alexa Fluor-555 conjugate Abs alone (4).
Panel 5 shows the merged images, and yellow-orange pixels indicate overlapping fluorescent signals; bars
indicate 10 m. All images were acquired with a 100 Plan NEOFLUAR oil immersion objective (NA 1.3)
mounted on a Zeiss Axiovert 100 confocal microscope. C, Western blot of total proteins of iDC (1  106
cell/lane) separated on a 6% SDS polyacrylamide gel. The blot was incubated with rabbit anti-Cav1.2 followed
by protein-G peroxidase. The immunoreactionwas visualized by chemiluminescence.D, reverse transcription-
PCR confirms the presence of the transcript for human Cav1.2 in iDC (see “Experimental Procedures” for details
of the experimental conditions and primers used).
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membrane potential caused by the Ca2 influx, K channels
(Kv1.3 and KCa) open, allowing efflux of K ions out of the T
cells, thus repolarizing the T cell membrane potential (37).
To determine whether these events (i.e. the K efflux fromT
cells and DHPR-RyR1 activation in DCs) are functionally cou-
pled in vivo, we studied if the direct interaction of antigen-
specific T cells with DCs causes an increase in MHC II surface
expression as well as an increase in the [Ca2]i of the DCs. To
carry out the in vivo experiments, we exploited the fact that T
lymphocytes fromABMRg/mice express a transgenic T cell
receptor which recognizes the class II MHC protein I-Abm12
expressed on the surface of DCs from BM12Ly5.1 mice but not
class II MHC protein I-Ab expressed on the surface of control
B6.Ly5.1 mice (24). CD11c-positive splenic DCs isolated from
B6.Ly5.1 or BM12Ly5.1 mice were co-centrifuged with T cells
from ABM Rg/ mice and incu-
bated an additional 5 min at 37 °C.
Cells were then diluted with ice-
cold PBS, stained with fluorescent
Abs, and analyzed by flow cytom-
etry. A further control consisting of
T cells pretreated with charybdo-
toxin to block K channels on T
cells was also included. This toxin
specifically blocks Kv1.3/KCa chan-
nels at nM concentrations and
inhibits K efflux (25). When DCs
from B6.Ly5.1 were incubated with
T cells, there was an approximate
2.5-fold increase in the level of
MHC class II molecules expressed
on splenic DCs, indicating that co-
centrifugation may non-specifically
activate toa lowextentbothcell types.
Interestingly, when BM12Ly5.1 DCs
were co-centrifuged with untreated
ABMRg/Tcells, therewasa5-fold
increase in the level of MHC class II
surface expression on splenic DCs
(Fig. 5B). This 5-fold increase in class
IIMHCexpression is specific as itwas
inhibited in the charybdotoxin-
treated T cell group, supporting the
idea that the full increase in MHC II
expression is due to specific T cell K
channel opening occurring as a con-
sequenceof theTcell/DCinteraction.
We used a similar approach to
confirm that the interaction of
BM12Ly5.1 DCs with ABM Rg/
T cells causes a ryanodine-sensitive
increase in the [Ca2]i of DCs. Fig.
5C shows a typical result obtained
after the addition of ABM Rg/ T
cells to Fluo-4-loaded BM12DCs.
As can be seen, the [Ca2]i of those
DCs which were found to have T
cells attached to them at the end of
the experiment (inset, Fig. 5C) was found to increase in an oscil-
latory manner. This event was not synchronized in the
responding cells as the moment of interaction between the two
populations of cells was not coordinated. In line with our
hypothesis, the increase in [Ca2]i induced by the
BM12Ly5.1DC Rg/ T cell interaction was most likely due to
opening of K channels on the T cells, as the Ca2 transients in
the DCs were profoundly diminished after pretreatment of T
cells with carybdotoxin (Fig. 5D). Finally, pretreatment of DCs
with 500 M ryanodine completely blocked the changes in
[Ca2]i (Fig. 5E).
DISCUSSION
In the present paper we investigated the signaling system
involving the RyR in iDCs and show that the upstream events
FIGURE 4. Pharmacological activation of RyR induces a rapid increase in membrane-associated MHC
class II molecules in iDC. A, iDCs were treated with 10 mM caffeine for the indicated time, labeled with
FITC-labeled anti-human HLA DR, fixed with paraformaldehyde, and analyzed by fluorescence-activated cell
sorter as detailed under “Experimental Procedures.” Results represent themean fluorescent intensity (S.E.) of
four experiments carried out on different donors. *, p  0.015. The inset shows a fluorescence-activated cell
sorter histogramshowingFITC fluorescence in immatureDCs (black line) and in iDCsafter theadditionof 10mM
caffeine for 1 min (gray line). B, iDCs were treated for 1 min with the indicated substance and processed as
described inA. Results represent themean S.E. of 4–6 experiments. Significant differenceswere observed in
the mean fluorescence intensity between iDCs and cells treated with necrotic cell extracts and between iDCs
and cells treated with 100 mM KCl; significant differences in mean fluorescence intensity were observed
between iDCs treated with necrotic cell extracts and KCl as compared with themean fluorescence intensity of
cells receiving similar treatments but preincubated with 10 M nifedipine or 20 M dantrolene; *, p  0.03;
**, p 0.05. C, iDCs were treated for 1min as indicated, labeled with FITC-labeled anti-human HLA A, B, C, and
processed for fluorescence-activated cell sorter analysis as described for A. Results represent the mean fluo-
rescence intensity (S.E.) of five experiments carried out on different DC donors. Mean fluorescence intensity
values were not significantly different in treated cells and iDC.
RyR1 Signaling in Dendritic Cells
DECEMBER 12, 2008•VOLUME 283•NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 34919
 at U
niversitaetsbibliothek M
edizin on M
ay 11, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
leading to Ca2 release via the RyR1 are similar to those occur-
ring in striated muscles and involve the functional interaction
with the DHPR L-type Ca2 channel. We also show that RyR1
activation has direct and rapid physiological consequences
leading to an increase in the level of MHC class II molecules on
the surface of iDCs within seconds.
Such a systemmay be important in
the very early stages of an infection
whereby prompt activation of the
adaptive immune system could
occur allowing rapid priming of T
cells without having to wait for
iDCs to undergo full functional
maturation.
Although the expression of the
RyR1 isoform in human and mouse
dendritic cells has been clearly
established (14, 16–17, 19), little
information if any is available con-
cerning its physiological mode of
activation. In fact, RyRs are intracel-
lular Ca2 channels localized on
sarcoplasmic reticulum/ER mem-
branes, and at least in excitable cells,
their activation is coupled to DHPR
L-type Ca2 channels present on
the plasma membrane (3, 4). The
latter channels have been character-
ized at the molecular, physiological,
pharmacological, and biophysical
level; they require strong depolariz-
ing signals to open, can be blocked
specifically by dihydropyridines and
other organic Ca2 channel block-
ers, act as voltage sensors mediating
Ca2 influx in response to mem-
brane depolarization, and regulate a
number of processes including
muscle contraction, insulin secre-
tion, neurotransmission, and gene
transcription (4). DHPRs are mac-
romolecular structures made up of
four or five distinct subunits that are
encoded by multiple genes. The 1
subunit constitutes the voltage sen-
sor and the pore and usually associ-
ates with the 1 and 2 subunits.
Although DHPRs are predomi-
nantly expressed in excitable tissues
such as neurons and muscle cells,
pancreatic cells, and endocrine cells
as well as T-lymphocytes have been
shown to express theCav1.2 isoform
of L-type Ca2 channels (38–40).
In an early report Poggi et al. (33)
showed that human DC express the
1 subunit of the DHPR as well an 
subunit because they were stained
with the fluorescent dihydropyridine analogue DM-BODIPY-
DHP. They also demonstrated the involvement of DHPR-sen-
sitive Ca2 channels in some DC functions such as apoptotic
body engulfment and interleukin-12 production. We have
extended these results and report that DCs have evolved a chi-
FIGURE5.SurfaceexpressionofMHCclass IImolecules ispromotedbyspecific T cell-DC interactionorby
KCl and necrotic cell extracts and is accompanied by an increase in the [Ca2]i in the DCs. A, % induction
in MHC II surface expression in CD11c-purified DCs isolated frommouse spleen cells after the addition of 100
mMKCl or necrotic cell extracts (mean%S.E.,n	 3–4 experiments); **, p 0.007. B, CD11c-positive dendritic
cellswere isolated from the spleens of either B6.C-H-2bm12Ly5.1mice (BM12DC) or B6.Ly5.1mice (control DC)
and co-centrifugedwith T cells isolated from lymph nodes of ABMRg/mice. T cells were either untreated or
preincubated with 100 nM charybdotoxin (Chyb tox) for 45 min to block Kv1.3 and IKCa1 channels. After co-
centrifugation, DC andT cellswere incubated an additional 5min at 37 °C. Cellswere thendilutedwith ice-cold
PBS, washed, and stained with FITC-labeled anti-mouse I-Ab monoclonal antibody, biotin-labeled anti-mouse
CD11c (Integrin x chain) monoclonal antibody, and PE-labeled anti-mouse CD45.1 monoclonal antibody.
After selection of triple positive cells by fluorescence-activated cell sorter, MHC II expression was analyzed.
Results are expressed as % increase in the mean fluorescent intensity compared with iDC (S.E. of three
experiments; **,p0.007).C–E showchanges in the [Ca2]i in fluo-4 loadedBM12DCafter the additionofABM
Rg/ T cells. Experiments were performed as described under “Experimental Procedures.” C, BM12DC T
cells.D is as in C except that T cells were preincubatedwith 100 nM charybdotoxin before addition to DCs. E, as
in C, except DCs were incubated with 500 M ryanodine during fluo-4 loading. Results are expressed as F/F0
where F is the fluorescent value at any given time, and F0 is the initial fluorescence level obtained at time 0.
Panels represent typical results obtained in six different experiments. Insets in panel C show brightfield pho-
tomicrographof BM12DCat t	0 andbrightfield epifluorescenceof fluo-4-loadedBM12DCat the endof the
experiment (250 s).Numbers indicateDCs thatwere analyzed andhadT cells (arrows) adjacent to them. Thebar
indicates 10 m.
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meric configuration, expressing the cardiac isoform of the 1
subunit (i.e. the Cav1.2 isoform), which functionally interacts
with the skeletal isoformof the RyR. The first question arising is
how can a functional coupling between the “cardiac” Cav1.2
isoform and the “skeletal” RyR1 isoform operate? In muscle
cells depolarization of the plasma membrane is sensed by the
Cav1, which acts as a voltage sensor activating the RyR to
release Ca2 from intracellular stores. In skeletal muscle the
Cav1.1 subunit and RyR1 interact directly (41–43), whereas in
heart cells, which express type 2 RyR, the Cav1.2 subunit acts
both as a voltage sensor and as a Ca2 channel, and the depo-
larizing signal allows Ca2 to flow into the cells from the extra-
cellular environment (44). It is the influx of Ca2 which acti-
vates RyR2 through a mechanism of Ca2-induced Ca2
release. We suggest that in DCs, coupling between the DHPR
and the RyR1 occurs as outlined in Fig. 9 of Schuhmeier et al.
(45); membrane depolarization caused by an increase in K is
sensed by Cav1.2 present on the plasma membrane of DCs.
Once activated, these channels allow Ca2 influx. In turn, this
local increase in [Ca2]i in the DCs activates RyR1 through a
Ca2 induced Ca2 releasemechanism. Such a configuration is
supported by the fact that RyR activation in DCs is strongly
dependent on extracellular Ca2 and can be blocked by nifedip-
ine. That this chimeric arrangement could function is sup-
ported by (i) the observation that electrical stimulation of dys-
genic myotubes (which express RyR1 but lack endogenous
DHPR), reconstituted with the cardiac Cav1.2, evokes myotube
contraction albeit only in the presence of Ca2-containing
medium (41) and (ii) by a report of Schuhmeier et al. (45) who
showed that different Cav channel isoforms (1.1, 1.2, and 2.1)
can functionally interact with RyR1.
The most intriguing questions arising from the observation
that DCs express DHPRs are how and when would these volt-
age-sensor-activated Ca2 channels be activated physiologi-
cally? Indeed DCs are not typically classified as electrically
excitable cells, yet we show that the addition of either necrotic
cell extracts or KCl both cause (i) plasma membrane depolar-
ization, (ii) nifedipine-sensitive increase in [Ca2]i, and (iii)
rapid and nifedipine-sensitive increase in surface expression of
MHC class II molecules. Necrotic and dying cells are present in
any tissue after extensive injury due to physical or mechanical
traumas, inflammation, or infections, and they can release a
number of factors and proteins including uric acid crystals, nucle-
ar-mobility group box 1 protein, and heat shock proteins (HSP96,
-90, -70andcalreticulin)whichcanall induceDCmaturation (46–
48). In addition, because the intracellular K concentration is
140 mM, dying cells will necessarily release K ions into the
extracellular medium; our results support the hypothesis that
necrotic cells may lead to activation of the DHPR-RyR signaling
pathway by releasing a number of factors, including K. This is
supported by the finding that necrotic extracts passed through a
0.22-m filter caused a nifedipine-and ryanodine-sensitive
increase in the [Ca2]i as well as membrane depolarization, but
extracts dialyzed against PBS using a 3000-kDa cut-offmembrane
did not alter the membrane potential. Because ions would be
removed by dialysis, these data suggest that K released from the
dead cells may be physiologically involved in the in vivo activation
of the DHPR-RyR1 signaling pathway.
Another important question is whether the DHPR-RyR1 sig-
naling pathway is only involved in the generation of co-stimu-
latory signals leading to DC maturation or whether it can rap-
idly and directly activate specific functions. Our results exclude
that endocytosis, a process intimately connected with iDC
function, and expression of MHC class I molecules on the
plasma membrane are influenced by activation of the RyR sig-
naling pathway. On the other hand, our results show that sur-
face expression of MHC class II molecules is rapidly (within
seconds) and significantly increased by the activation of the
RyR1 signaling pathway. DCs synthesize large quantities of
MHC class II molecules which classically bind peptides derived
from endocytosed proteins and present them on their surface
for interaction with T cells to initiate a specific immune
response. They also express empty MHC II molecules on their
surface as well as sequestered MHC class II molecules within
intracellular compartments (22, 49). These sequestered mole-
cules apparently reside unproductively within the cell. The
results of the present study indicate that activation of the
DHPR-RyR1 pathway causes expression of preformed MHC
class II molecules on the surface of DCs. Empty surfaceMHC II
molecules can be loadedwith antigenic peptides from the extra-
cellular medium, allowing even immature DCs to present pep-
tides to T cells without intracellular processing (50, 51). We
hypothesize that RyR1 activation in DCs leads to the rapid sur-
face expression of sequestered MHC II molecules. This would
be particularly important for iDC and T cells to interact effi-
ciently directly in an inflamed tissue where dead or dying cells
are present, leading to the rapid amplification of a specific
immune response. Such a rapid activationmust be strictly con-
trolled and most likely requires T cells and iDCs to generate
orthograde and retrograde signals, which would strengthen the
intracellular signals generated and lead to T cell-dependent
immune responses. That T cells are capable of releasing soluble
factors which trigger DCs is substantiated by our findings that
FIGURE 6. Schematic depicting the model of RyR1-dependent signaling
pathways in DC. KCl released from dead cells in the vicinity of DCs causes
membranedepolarization,which is sensedby theDHPRvoltage sensor. Alter-
natively, interaction of T cells with iDC, strong enough to activate an increase
in the [Ca2]i via release from intracellular stores andactivationof Ca
2 influx,
is accompanied by efflux of K to repolarize the T cell membrane potential.
This K is releasedonto the iDCs and canbe sensedby theDHPR. This leads to
activation of the RyR1 signaling pathway causing the rapid expression of
MHC class IImolecules onto the surface of iDCs. The lattermolecules could be
loaded with antigenic peptides and interact in situ with T cells to initiate an
early and rapid specific immune response. TCR, T cell receptor; CRAC, Ca2
release activated Ca2 channel.
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the direct interaction of murine T cells with a transgenic T cell
receptor specific for the I-Abm12 protein and BM12Ly5.1DC
(which express the I-Abm12) causes (i) a 5-fold increase in sur-
face expression ofMHCclass IImolecules and (ii) an increase in
theCa2 in theDCswhich is sensitive to high concentrations of
ryanodine, which inactivate the RyR Ca2 channel (30, 31), and
charybdotoxin, which blocks K channels on T cells. We sug-
gest that the increase inMHC II surface expression is promoted
by efflux of K via channels present on the surface of T cells
which open after the increase in [Ca2]i triggered by engage-
ment of the T cell receptor. This idea is supported by the obser-
vation that up-regulation of MHC II could be blocked by pre-
treatment of T cells with the K channel toxin charybdotoxin.
A schematic outlining this hypothesis is depicted in Fig. 6.
In conclusion we present evidence that the DHPR-RyR1 sig-
naling machinery plays an important role in up-regulation of
MHC class II molecules on the surface of DCs, and this signal-
ing pathway could be an important target for drugs aimed at
improving the immune system by increasing the efficiency of
antigen presentation or at impairing the immune system by
decreasing presentation of autoantigens responsible for the
induction of autoimmune disorders.
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